Investor & Analyst Day 2015: Closing Remarks (8/8)
-
Upload
exact-sciences -
Category
Investor Relations
-
view
604 -
download
2
Transcript of Investor & Analyst Day 2015: Closing Remarks (8/8)
![Page 1: Investor & Analyst Day 2015: Closing Remarks (8/8)](https://reader036.fdocuments.in/reader036/viewer/2022071903/55c52d4fbb61eb71638b45ef/html5/thumbnails/1.jpg)
![Page 2: Investor & Analyst Day 2015: Closing Remarks (8/8)](https://reader036.fdocuments.in/reader036/viewer/2022071903/55c52d4fbb61eb71638b45ef/html5/thumbnails/2.jpg)
2
The information and data presented here was prepared for investors and potential investors. It includes forward-looking information on investigational products in development that are not available for sale in the United States. These include early-stage development products for which the performance characteristics have not yet been established.
![Page 3: Investor & Analyst Day 2015: Closing Remarks (8/8)](https://reader036.fdocuments.in/reader036/viewer/2022071903/55c52d4fbb61eb71638b45ef/html5/thumbnails/3.jpg)
Investor & Analyst Day key takeaways
Cologuard® execution: Offering significant benefits to patients
and providers through advanced screening; ramp accelerating
Management strength: Experienced team and track record of execution
Impactful pipeline: Leveraging first-of-its-kind commercial product
to increase shareholder value
Industry leader: Product development, regulatory reviews
and commercialization
![Page 4: Investor & Analyst Day 2015: Closing Remarks (8/8)](https://reader036.fdocuments.in/reader036/viewer/2022071903/55c52d4fbb61eb71638b45ef/html5/thumbnails/4.jpg)
Exact Sciences is committed to helping win the war on cancer through
early detection
OUR VISION
![Page 5: Investor & Analyst Day 2015: Closing Remarks (8/8)](https://reader036.fdocuments.in/reader036/viewer/2022071903/55c52d4fbb61eb71638b45ef/html5/thumbnails/5.jpg)
5